Maternal outcomes of magnesium sulphate and diazepam use in women with severe pre-eclampsia and eclampsia in Ethiopia
Background: Preferred anticonvulsant used to treat and prevent fits in eclampsia currently is magnesium sulphate. Clinical monitoring of tendon reflexes, respiration rate and measuring hourly urine output should be done to ensures safe administration of magnesium sulphate
Objective: This study was conducted to evaluate maternal outcomes of magnesium sulphate and diazepam use in the management of severe pre-eclampsia and eclampsia in Jimma University Specialized Hospital.
Methods: A retrospective hospital based cross-sectional comparative study was conducted using data collection format. Data was collected from the hospital delivery care register and patient chart records of all pregnant women who presented with the diagnosis of severe pre-eclampsia and eclampsia in two years and three months period from January, 2010 to April, 2012. Data analysis was done by SPSS version 16.0. A P-value of <0.05 was considered statistically significant in all tests.
Results: A total of 357 patient charts, 217 from magnesium sulphate and 140 from diazepam treated pregnant women group, were reviewed and analyzed. Three pregnant women from the magnesium sulphate treated group and eleven pregnant women from diazepam treated group had at least one convulsion after taking the drug. Greater proportion of patients in the magnesium sulphate treated group had less than four days postpartum stay as compared to the diazepam treated patients (82.3% versus 66.2%). Seizure occurrence, duration of postpartum hospital stays and birth outcome had a statistically significant association with the type of anticonvulsant used.
Conclusions: Magnesium sulphate is more effective than diazepam in the management of severe pre-eclamptic and eclamptic pregnant women in terms of seizure prevention, shortening postpartum hospital stay and reducing maternal morbidities.
2. Mundle S, Regi A, Easterling T, Bivas Biswas B, Bracken H, Khedekar V, Shekhavat DR, Durocher J, Winikoff B. Treatment approaches for preeclampsia in low-resource settings: A randomized trial of the Springfusor pump for delivery of magnesium sulfate. Pregnancy Hyperten. 2012;2(1):32-38. doi:10.1016/j.preghy.2011.09.002
3. Gracia VD. Maternal deaths due to eclampsia and HELLP syndrome. Int J Gynaecol Obstet. 2009;104(2):90-94. doi: 10.1016/j.ijgo.2008.09.014
4. Duley L, Gulmezoglu A. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev. 2001;(1):CD002960.
5. Drug Aministration and Control Authority E. Standard treatment guidelines for zonal hospitals. Obstetrics and gynecological conditions. Addis Ababa 2010. p. 265-266.
6. Ministry of Health FDRE. Management Protocol on Selected Obstetrics Topics. Addis Ababa 2010. p. 181-182.
7. Muganyizi P, Shagdara M. Predictors of extra care among magnesium sulphate treated eclamptic patients at Muhimbili National Hospital, Tanzania. BMC Pregnancy Childbirth. 2011;11:41. doi: 10.1186/1471-2393-11-41
8. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D; Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo controlled trial. Lancet. 2002;359(9321):1877-1890.
9. Tukur J, Muhammad Z. Management of eclampsia at AKTH: before and after magnesium sulphate. Niger J Med. 2010;19(1):104-107.
10. ESOG. Magnesium Sulphate use for prevention of Preeclampsia and Eclampsia related mortality in Ethiopia 2011; Available from: http://www.esog.org.et/Projects.htm (accessed 2012 February 3).
11. Office JUER. Jimma University Specialized Hospital and Existing medical services 2012. Available from: http://www.ju.edu.et/jimma-university-specialized-hospital-jush (accessed 2012 February 3).
12. Wolde Z, Segni H, Woldie M. hypertensive disorders of pregnancy in Jimma University Specialized Hospital. Ethiop J Health Sci. 2011;21(3):147-154.
13. Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet. 1995;345(8963):1455-63.
14. Chaudhary P. Eclampsia: before and after magnesium sulphate. JNMA J Nepal Med Assoc. 2005;44(160):124-128.
15. Tannirandorn Y. Is magnesium sulfate for prevention or only therapeutic in preeclampsia. J Med Assoc Thai. 2005 Jul;88(7):1003-1010.
16. Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;(11):CD000025. doi: 10.1002/14651858.CD000025.pub2
17. Getaneh W, Kumbi S. Use of magnesium sulfate in pre-eclampsia and eclampsia in teaching hospitals in Addis Ababa: a practice audit. Ethiop Med J. 2010;48(2):157-164.
18. Ikramullah K, Ambreen, Humera. Magnesium Sulfate Versus Diazepam Infusion in Eclampsia. Annals of King Edward Medical University. 2009;15(3):149-151. Available at http://www.annalskemu.org/journal/index.php/annals/article/viewArticle/84
19. Ola RE, Odeneye O, Abudu OO. Eclampsia: A Randomized Double Blind Trial of Magnesium Sulphate and Diazepam in Lagos, Nigeria. Trop J Obstet Gynaecol. 2005; 21(2):143-147.
20. Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for eclampsia (Review). Cochrane Database Syst Rev. 2010;(12):CD000127. doi: 10.1002/14651858.CD000127.pub2
21. Sharma R, Sharma V. Effect of magnesium sulphate versus phenytoin on the hospital length of stay of patients of eclampsia and severe preeclampsia. Journal of Chemical and Pharmaceutical Research 2012;4(4):1921-1924. Available at http://jocpr.com/vol4-iss4-2012/JCPR-2012-4-4-1921-1924.pdf
22. MCHIP. Report of second technical working group meeting on pre-eclampsia/eclampsia. Washington, DC.2009.
23. Coalition RHs. Product Brief Caucus on New and Underused Reproductive Health Technologies 2012.
24. Engender Health. A Report on Barriers and Solutions to Treat Pre-eclampsia & Eclampsia 2007
25. Ugwu EO, Dim CC, Okonkwo CD, Nwankwo TO. Maternal and perinatal outcome of severe pre-eclampsia in Enugu Nigeria after introduction of Magnesium sulfate. Niger J Clin Pract. 2011;14(4):418-421. doi: 10.4103/1119-3077.91747
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.